OncoMatch/Clinical Trials/NCT06908694
Investigation of GLP1-Receptor Agonists in Men With Prostate Cancer Taking Androgen Deprivation Therapy
Is NCT06908694 recruiting? Yes, currently enrolling (May 2026). This Phase 4 trial studies Semaglutide Pen Injector for prostate cancer.
Treatment: Semaglutide Pen Injector — GAIN PC CONTROL is a study investigating Glucagon-Like Peptide-1 Receptor Agonists in men with prostate cancer who are being treated with androgen deprivation therapy.
Check if I qualifyExtracted eligibility criteria
Cancer type
Prostate Cancer
Prior therapy
Must have received: androgen deprivation therapy (gonadotropin releasing hormone agonist, gonadotropin releasing hormone antagonist, androgen receptor pathway inhibitor) — receiving or planned to receive
Must be receiving or planned to receive ADT (gonadotropin releasing hormone agonist or antagonist ± androgen receptor pathway inhibitor)
Cannot have received: GLP-1 receptor agonist
Taking a GLP-1 RA
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify